But in all of these short-acting strategies, they are relying on Opioids. And so as we move forward here, our strategy is not only to be able to be cost conscious given the struggles of our customers, but also to be able to provide a long-acting product so that they can reduce Opioids. So none of these strategies that you’re hearing where people are going to lower-cost products allow them to have anything that works for more than 10 to 12 hours and all of those strategies rely on opioids. And we think that we can do better than that.
Unidentified Analyst: Thanks.
Operator: Thank you. Our next question is from Oren Livnat from H.C. Wainwright. Your line is open.
Oren Livnat: Thanks. I have a couple of questions. If I could just follow-up on Dave, your earlier comments about growth generally this year coming or maybe entirely coming from contracted customers, whether that’s 340B or other contracts or I guess, as you said, price-protected customers going forward in 2024 and beyond. How do you feel about organic growth? I guess you could call it across the entire book of business, including the non-contract business. Should we think that where you were able to penetrate, you’ve hit a ceiling that just is what it is without further price action or help or is it just a function of the market is still making to normalize? And next year, you do see growth across that book two? And I have a follow-up.
Dave Stack: No. Well, we believe that it’s a both. All right. Thank you for the question, by the way. We think lower extremity nerve block. Well, first of all, we think that the market normalization and the – it sounds more of it when I talk about it this way, but I don’t mean it that way. But the pipeline of patients will require largely soft tissue procedures as disease progression, largely in the cancer population goes forward, that population that I talked about earlier that was absent for 2022 and 2023 because of the mortality associated with the pandemic We think that, that’s fact. So we think procedure normalization means the procedures will grow at a slightly higher rate to start with. Then we add no pain to that — or we had a lower extremity nerve block to that, which should, by the way, be sponsored to a greater degree because of our relationship with the ASA.
We will have specific activities that are directed by the ASA, as a result of the neuro – lower extremity nerve block launch. And then as we get into 24 range, we have the combination of these cocktails and we believe that there will be some ability to take these products off the market, which will move more of these procedures back to EXPAREL, especially the lower dose of EXPAREL, and at the same time, our GPO contracts will provide a broader base of contracted business, which is where we saw the growth in 2024. So we really — I see it — we see it as 2.5 buckets. The half bucket is procedure normalization and the two buckets are lower extremity nerve block in combination with the ASA and the anesthesiologists having increased interest in a 10 ml dose, again, addressing the cost issue.
And then the whole opportunity to broaden our contract base with GPOs, eliminate some of the higher percentage rate, individual contracts that we have with specific health plans. And then at the same time, allow those folks to start to use EXPAREL against some of these cocktails, which as stated earlier, are not FDA approved that are only short-acting products in the best case, which require that they use opioids and really, the clinicians are not happy with those decisions at all. Those decisions are being made purely by kind of cost alone by pharmacy and in some cases, by C-suite initiatives.
